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Background: There have been antidiabetic claims for Aloe vera (AG)
Barbadensis Mill. gel and infusion of Cnidoscolus chayamansa (CC)
McVaugh.
Objectives: To determine if the ingestion of total process AG
concentrated 5:1 (TA), AG, CC or placebo can reduce hyperglycemia
in women with early metabolic syndrome (EMS).
Methods: One hundred-twenty five women from two outpatient
university clinics were randomly assigned to a three assay double-
blind crossover procedure. Subjects were adult women with EMS
by ATP III criteria assigned to assay 1: AG&CC vs P1&P2; assay 2:
AG&P2 vs P1&CC; or assay 3: TA vs P3. All assays included the
ingestion of one, then zero (washout period), then two gelatins/day,
for 4, 1, 4 weeks, respectively. The expected outcome was an HbA1c
decrease 4.2 mmol/mol or lower but sustaining euglycemia.
Results: Participants had a mean age of 46.8 ± 9.7 years and a
mean HbA1c of 47.8 ± 12.7 mmol/mol at the start of the study. The
least tolerated combination was AG&P2. Patients complained of
bad taste and mild stomach pain because of the double dose of this
treatment; this caused withdrawals: 4/25 vs. 9/21, respectively, Chi
square ¼ 4.1, df ¼ 1, P < 0.05. Changes in HbA1c (mmol/mol) were
assay 1, 1.8 ± 7.5 vs 1.6 ± 6.9, P > 0.05; assay 2, 1.3 ± 6.6 vs
1.4 ± 7.6, P > 0.05; assay 3, 4.9 ± 8.3 vs 0.44 ± 5.4, P < 0.01,3.
s-Ibarra).
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protein (hs-CRP) (P < 0.05).
Conclusions: Data suggest that TA decreases blood glucose levels
by reducing the proinflammatory state. The infusion of microwave
dehydrated CC leaves did not reduce blood glucose or HDL and
triglyceride levels.
Clinical Trails.gov Identifier: NCT00916175.
© 2017 The Authors. Published by Elsevier Ltd on behalf of
European Society for Clinical Nutrition and Metabolism. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Metabolic syndrome is defined as the presence of at least three of the following: hypertension,
central obesity, and high blood levels of glucose, cholesterol, and inflammatory markers. A genetic
predisposition, bad dietary habits, and a sedentary life style are also present in these patients. In the
United States, there is a prevalence of metabolic syndrome of 34.5% in individuals over 20 years of age
[1]. In Monterrey, Mexico, the prevalence of high blood pressure, diabetes mellitus and glucose
intolerance in adults was 26%, 14% and 19%, respectively. Most of these individuals had central obesity
[2]. Weight loss is key to treating this highly extended condition. However, people often fail to lose
weight or regain the weight soon after it is lost [3].
Functional foods are defined as foods that are consumed as part of a usual diet but have physio-
logical effect and/or reduce the risk of chronic disease beyond basic nutritional functions [4]. Reports
show that Aloe vera (Barbadensis Miller) gel (AG) contains nutrients and functional activities such as
decreasing hyperglycemia [5,6]. Perez et al. [7] also reported that a polyphenol extract from A. vera gel
decreased glucose levels in induced insulin resistance inmice. Another plant with antidiabetic effects is
C. chayamansa (McVaugh) (CC) used as an infusion [8]. Gonzalez-Laredo et al. [9] described that the
antidiabetic properties of CC could be due to its high content of flavonoids, which are most commonly
known for their antioxidant activity [10]. Although their active principals have not been well charac-
terized and the scarcity of clinical studies hamper an informed decision, people still use them [11].
We undertook this study to determine if the daily ingestion of concentrated 5:1 AG by total process
(TA), AG or CC infusion vs. placebo reduces high blood glucose levels in women with early metabolic
syndrome.
2. Materials and methods
Three controlled clinical procedures were performed. Each with two treatment sequences, cross-
over, and double blind randomization as follows: assay 1: AG&CC vs P1&P2; assay 2: AG&P2 vs
P1&CC; assay 3: TA vs P3.
The study took place in two outpatient clinics: one at a university hospital (Monday to Friday) and
another at a low-income community health center (Saturdays). Enrollment took place from Oct 15,
2008 to December 20, 2008; follow up ended on March 26, 2009. Subjects were adult women with
early metabolic syndrome (EMS); i.e., with at least three of the ATP III clinical identification criteria
[12]: waist circumference 88 cm, fasting capillary blood glucose 100 mg/dL, known arterial hy-
pertension, or arterial blood pressure 130/85 mm/Hg (two out of three measurements in the
morning), triglycerides 150 mg/dL, and an HDL <50 mg/dL. Women who were pregnant or nursing,
had hyperglycemic symptoms, were on hypoglycemic agents, or with a previous diagnosis of diabetes
melllitus (DM), had advanced DM complications, dementia, a non-compensated endocrinopathy, or
severe behavioral problems were excluded.
The protocol was previously approved by the University Hospital Ethics Committee and Research
Committee (registration no. EN08-027). The study complied with the Helsinki declaration and all
participants provided signed informed consent.
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among treated groups and a power index of 2.8 (two-tiled alpha 5% and one-tiled beta 20%). Thus, a
sample of 44 subjects per group was needed [13]. There were 44 in the AG group, 44 in the CC group,
and only 22 in the TA group, since it is concentrated 5:1 AG. Fifteenmorewere added to compensate for
possible dropouts, giving a total of 125 subjects.
Randomization was carried out using 125 sequentially numbered envelopes enclosing the code
treatment with a computer-generated random number. To ensure balance, every ten envelops had 2
assignments for each of the treatments in assay 1 and 2, but only one each for TA and P3 in assay 3
(Fig. 1). To reveal the assignment code, the corresponding envelope was opened after the identified
eligible subject had signed the informed consent provided by the coordinator. Decoding only took place
in patients with suspected moderately severe side effects and after data analysis. Treatments were
disguised in 230 ml lemon gelatins. These could contain AG&CC¼ 30 ml of A. vera gel and 200 ml of CC
infusion; P1&P2¼ 30ml of placebo 1 and 200ml of placebo 2; AG&P2¼ 30ml of A. vera gel and 200ml
of placebo 2; P1&CC¼ 30 ml of Placebo1 and 200ml of CC infusion; for TA¼ 30 ml of concentrated 5:1
AG (5 L of AG to obtain 1 L of total aloe) and 200ml of water; lastly, for group P3, 30ml of stabilizers and
a colorant without TA and 200 ml of water.
2.1. Plant material
Whole fresh leaves of A. vera (AG) were obtained from an internationally certified organic farm
(Aloe Jaumave, S.A de C.V., Jaumave, Tamaulipas, Mexico); manually obtained crystalline gel without
the yellow latex of the leaves. The gel was liquefied and aliquoted 30 ml per gelatin. Patented Totaloe
(TA) concentrated 5:1 AG by total process was obtained from the same organic farm, also in aliquots of
30 ml per gelatin. TA was chromatographically defined as aloeride 2.56%, acemannan 8.77%, manapol
35.49%, aloemannan 19.30%, and small molecular species 33.88% by the North Texas Research Lab (Nov.
2009, Danhof, Ivan E.)
CC leaves were obtained from a local garden. The plants satisfied the morphology description by
Kuti et al. [8] and Stephens [14]. To ensure a sanitized supply, CC leaves were washed and rinsed with
tap water and then air dried and later microwave dehydrated. The infusion was prepared as follows:
10 g of dry leaves per 11.5 L of water heated at ~80 C to reduce 1.5 L for a final 10 L of CC infusion. The
gelatin dose was 200 ml.
Placebo 1 was one milliliter of green food colorant per 10 L of purified water to be used 30 ml per
gelatin. Pacebo 2 was one milliliter yellow food colorant per 10 L of purified water utilized 200 ml per
gelatin. Placebo 3 consisted of the same stabilizers and colorant for TA but without TA (Aloe Jaumave,
S.A de C.V.). Production records and coded gelatin labels were used.
The assigned treatment was one lemon gelatin per day for four weeks. During the fifth week no
gelatin was supplied (washout period), then a crossover to the opposite group was performed for a
second treatment period of 4 weeks, increasing the dose to two lemon gelatins every day (Fig. 1). Three
blood samples were taken, one at baseline and one at the end of each treatment period. A diet of 1500
calories was prescribed to each participant, along with a written guide to remember diet instructions.
Seventy-four participants underwent a third treatment period. They were single blinded and assigned
to either: AG&CC, AG&P2, P1&CC, or TA. Two gelatins per day were provided. One more blood sample
was drawn after the 4th week. Clinical data and lab reports were handled independently. Participants
learned their health status at the time of recruitment; however, subsequent lab test results were
withheld until the data analysis was done.
A reduction of an elevated glycohemoglobin A1c fraction (4.2 mmol/mol) was considered success.
Likewise smaller variations that sustain HbA1c under 42.0 mmol/mol were also considered a success.
The secondary outcome was a reduction of the BMI, proinflammatory hs-CRP levels, and HDL and
triglyceride levels.
Safety was monitored by a complete blood cell count and liver function tests at baseline and after
each treatment. Tolerance was evaluated by weekly questioning the effort to take the treatment
(gelatin), the sense of wellbeing, energy, and satiety level, gastrointestinal (bowel movements), and
general complaints. Any complaints of malaise were considered potential side effect unless another
diagnosis was made.
Fig. 1. Work flow algorithm: AG ¼ Aloe vera gel; CC ¼ Cnidoscolous chayamansa infusion; TA ¼ concentrated 5:1 AG by total process;
P ¼ placebo (1, 2 and 3). Hexagons show drop out reason: lc ¼ lost contact, mr ¼medical reason, wd ¼ withdraw consent, SE ¼ side
effect, nc ¼ non compliant. All SE were mild, no requiring medication but one subject took a butyl bromide tablet; 61% of subjects
with any SE did not drop out (see Table 1). Lab determinations were blinded.
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test (One-HbA1c FS) via Star-Dust MC15 (both from DiaSys Diagnostic Systems, Wixom, MI). Their
coefficient of variation was 1.6%. High sensitive C-reactive protein (hs-CRP) was measured using an
IMMULITE immunoassay analyzer (Siemens Healthcare Diagnostics, Erlangen, Germany). Triglycerides
and HDL cholesterol levels were determined manually with RANDOX kits (Randox Laboratories Ltd.
London, UK) using the GPO-PAP method and precipitation with phosphotungstic acid/MgCl2,
respectively.
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malaise complaints were analyzed with Fisher's exact test. Recurring HbA1c was tested by the non-
parametric Friedman procedure. Next, an intraassay comparison of groups was performed by inde-
pendent t, for treatment effect. Paired t and/or theWilcoxon test were used to assess treatment change
of HbA1c, hs-CRP, DHL-C, triglycerides, body weight in kg and body mass index (BMI) kg/m2. A baseline
comparison within assays and the six treatments used were made with the KruskaleWallis test and a
one-way ANOVA. Dunnett's procedure was used for multiple comparisons versus a selected treatment
with one side significance. Linear regression was performed for period I, parameterization: aloe dose
(0 ¼ none [placebo], 1 ¼ AG, and 2 ¼ TA), CC (0 ¼ none [placebo], 1 ¼ 200 or 400 ml of CC infusion).
Two-sided alphawas considered (unless otherwise specified); significance was set at 0.05, and a trend,
between 0.05 and 0.1. The intention-to- treat analysis drop outs were handled in two ways: 1) counted
as a failure (A1c increase 5.7 mmol/mol) in their corresponding group, and 2) last observation carried
forward (LOCF) [13].
3. Results
The flow chart of the 125 recruitedwomenwith EMS is shown in Fig.1. Baseline characteristics were
similar across the groups. Collectively mean age ± SD was 46.8 ± 9.7 years, BMI was 34.0 ± 5.2 kg/m2,
body weight was 82.1 ± 14.8 kg, waist circumference was 101 ± 11.1 cm, HbA1c was 47.8 ± 12.7 mmol/
mol, hs-CRP 6.3 ± 6.5 mg/L, HDL 47.5 ± 10.3 mg/dl and triglycerides 133.1 ± 94.8 mg/dl. Overall, after
the first and second treatment periods, and LOCF for dropouts, HbA1c improved to 43.8 ± 9.9 and
42.4 ± 10.1 mmol/mol, respectively (Friedman's c2 ¼ 72.2, df ¼ 2, P < 0.001).
3.1. Tolerance and safety
Subjects' compliance and side effects (SE) are shown in Table 1. A double gelatin dose (second
treatment period) increased the number of subjects dropping out collectively reaching significance for
the AG&P2 and P3 treatments; likewise for any SE reported (P < 0.05). Sleep disturbances and a
peculiar sweat odor were reported for CC and was dose independent. Colonic malaise and unpalatable
gelatin treatment predominated with A. vera (AG&P2 and TA). The main complaint with placebo was
upper gastric discomfort (heartburn, more hunger, etc.). AG&CC had the fewest dropouts and SE, and
also showed the best rank of wellbeing and energy level sensed by the patients in both treatment
periods (Table 2); but this decreased in the second period for all treatments reaching significance for P3
and AG&P2. Safety surveillance, blood cell counts and liver function tests, were normal across assays
(data not shown). SE (malaise complaints) improved without medication in all subjects except in one
who took a butyl bromide tablet. Of those with any malaise complaints, 61% did not drop out.
3.2. Effect on blood glucose level
In an intra-assay comparison, the HbA1c mmol/mol change for AG&CC vs P1&P2, AG&P2 vs P1&CC,
and TA vs P3 was 1.8 ± 7.5 vs 1.6 ± 6.9, t ¼ 0.1, df ¼ 93, P > 0.1; 1.3 ± 6.6 vs 1.4 ± 7.6, t ¼ 0.07,
df ¼ 90, P > 0.01; 4.9 ± 8.3 vs 0.4 ± 5.4, t ¼ 2.7, df ¼ 49, P < 0.01, respectively. Data by assay,
treatment and period are shown in Table 3. TA had a significant improvement and its HbA1c changewas
divergent from the one shown for P3 in both periods (P < 0.05). AG&CC and AG&P2 tended to improve
(P < 0.1) in the first period only. Indeed, LOCF for drop outs, AG&CC results change insignificantly but
AG&P2 improvement reached significance in both periods; however, it was not statistically divergent
from its counterpart (P1&CC). Comparison for the six treatment sequences, using LOCF for drop outs,
revealed a trend by KruskaleWallis c2 ¼ 10.5, df 5, P < 0.08 with TA 5.72 ± 7.4 mmol/mol producing
the greatest improvement; its differences (±SE) versus AG&CC, P1&P2, AG&P2, P1&CC, and P3 were:
3.5* ± 1.6, 3.0x ± 1.5, 2.9 ± 1.6, 3.4x ± 1.6, and 4.8* ± 1.8 respectively; one sided xP < 0.1;
*P < 0.05 using Dunnett's multiple comparison test.
The results of period III with a single-blinded convenient assignment are displayed in Table 4. The
groups containing CC worsen as they show a significant increase of HbA1c (both P < 0.05), while aloe
groups had a non-significant variation sustaining a mean in the euglycemia range. Between groups
Table 1
Protocol compliance and side effects (SE).
Period All treatments Assay1 Assay2 Assay3
AG&CC P1&P2 AG&P2 P1&CC TA P3
I II I II I II I II I II I II I II
n 124 (100) 113 (100) 24 (100) 22 (100) 26 (100) 23 (100) 25 (100) 21 (100) 24 (100) 22 (100) 12 (100) 14 (100) 14 (100) 11 (100)
Abandon 15 (12.1) 29(25.7)** 1 (4.2) 3 (13.6) 5 (19.3) 5 (21.7) 4 (16.0) 9(42.9)* 4 (16.7) 4 (18.2) 1 (8.3) 3 (21.4) 1 (7.1) 5(45.5)*
Any SE 24 (19.4) 33(29.2)x 2 (8.3) 6(27.3)x 4 (15.4) 5 (21.7) 5 (20.0) 10(47.6)x 7 (29.2) 4 (18.2) 4vs3 3 (21.4) 3 (21.4) 5 (45.5)
Insomnia 5 (4.0) 7 (6.2) 1 (4.2) 2 (9.0) 0 (0.0) 1 (4.3) 0 (0.0) 1 (4.8) 4 (16.7) 3 (13.6) 0 (0.0) 0 (0.0) 0 (0.0) 1 (9.1)
Nocturia 2 (1.6) 7(6.2)x 0 (0.0) 2 (9.0) 0 (0.0) 1 (4.3) 0 (0.0) 3(14.3)x 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.1) 1 (9.1)
Headache 4 (3.2) 7 (6.2) 0 (0.0) 2 (9.0) 0 (0.0) 1 (4.3) 1 (4) 2 (9.5) 1 (4.2) 0 (0.0) 1 (8.3) 1 (0.7) 1 (7.1) 1 (9.1)
PSO 1 (0.8) 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.2) 1 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Dyspepsia 8 (6.5) 8 (7.1) 1 (4.2) 0 (0.0) 4 (15.4) 3 (13.0) 0 (0.0) 1 (4.8) 1 (4.2) 2 (9.0) 1 (8.3) 1 (0.7) 1 (7.1) 1 (9.1)
Colitis 5 (4.0) 9 (8.0) 0 (0.0) 2 (9.0) 0 (0.0) 0 (0.0) 3 (12.0) 2 (9.5) 1 (4.2) 0 (0.0) 1 (8.3) 2 (14.3) 0 (0.0) 3(27.3)x
Unpalatable 3 (2.4) 5 (4.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3(14.3)x 0 (0.0) 0 (0.0) 3 (25.0) 1 (0.7) 0 (0.0) 1 (9.1)
AG ¼ Aloe gel; CC¼ Cnidoscolous chayamansa infusion; TA ¼ concentrated 5:1 AG by total process; P ¼ placebo (1, 2 and 3).
PSO ¼ peculiar sweat odor. Boxed data mean predominance of SE regardless of period (double dose in period II).
Data are n(%). I vs. II period Fisher's exact test, one side probability: §P < 0.1; *P < 0.05; **P < 0.01.
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Table 2
Mean rank of subjects' reported wellbeing, energy, and satiety level.
Period Assay1 c2 Assay2 c2 Assay3 c2
AG&CC P1&P2 AG&P2 P1&CC TA P3
I II I II I II I II I II I II
N 24 22 26 23 25 21 24 22 12 14 14 11
Wellbeing 65 58 41 30 25.0** 48 40 43 54 3.7 28 30 28 17 5.1
Energy 64 60 41 27 28.3** 48 38 44 55 4.7 27 32 27 16 7.7x
Satiety 63 47 41 41 10.6* 51 43 47 43 1.5 30 29 25 20 3.7
AG ¼ Aloe gel; CC ¼ Cnidoscolous chayamansa infusion; TA ¼ concentrated 5:1 Aloe gel by total process; P ¼ placebo, 1, 2 and 3.
Data ¼Mean rank. The largest rank decrease is underlined. Intra-assay test were KruskaleWallis c2, with 3 degrees of freedom.
Wellbeing, energy and satiety ¼ sensed level. Significant values in bold §P < 0.1; *P < 0.05; **P < 0.01.
TA vs. P3 increase level of wellbeing ¼ 19/26 vs. 11/25; and for energy: 22/26 vs 14/25, each c2 > 4.4, df 1, P < 0.05.
Table 3
Mean ± SD of pre and post treatment HbA1c mmol/mol, by period and assay.
Period I Assay 1 KW
c2
Assay 2 KW
c2
Assay 3 KW
c2
AG&CC P1&P2 AG&P2 P1&CC TA P3
N ¼ 24 N ¼ 26 N ¼ 25 N ¼ 24 N ¼ 12 N ¼ 14
PreTx HbA1c 47.45 ± 11.13 46.6 ± 9.1 0.30 46.3 ± 7.9 46.2 ± 9.3 0.45 49.4 ± 16.4 51.2 ± 23.7 0.01
PosTx HbA1c 44.22 ± 8.2 44.2 ± 6.1 0.31 43.9 ± 9.9 45.1 ± 9.2 1.1 42.7 ± 11.8 50.6 ± 18.9 3.0x
Diff. low-up 95% CI ¡0.3 to 6.8x 0.9 to 5.8 0.1 ¡0.5 to 5.3x 2.2 to 4.4 0.1 0.3 to 13.0* 2.9 to 4.1 3.8*
Period II Crossover Crossover Crossover
N ¼ 22 N ¼ 23 N ¼ 21 N ¼ 22 N ¼ 14 N ¼ 11
PreTx HbA1c 42.48 ± 4.84 43.84 ± 8.3 0.01 42.9 ± 6.0 43.1 ± 10.7 0.36 49.3 ± 19.2 43.4 ± 12.2 1.2
PsTx HbA1c 42.33 ± 8.10 43.13 ± 7.7 0.94 42.9 ± 8.2 41.43 ± 8.4 0.43 45.9 ± 19.1 45.2 ± 13.6 1.6
Diff. low-up 95% CI 2.5 to 2.8 1.4 to 2.8 0.22 2.7 to 2.6 1.6 to 5.0 1.24 ¡0.4 to 7.1x 4.6 to 1.0 4.3*
AG ¼ Aloe gel; CC ¼ Cnidoscolous chayamansa infusion; TA ¼ concentrated 5:1 Aloe gel by total process; P ¼ placebo (1,2 and 3).
PreeposTx ¼ pre and post treatment. Drop outs count as failure (HbA1c increase 5.7 mmol/mol). Data: median, sum /þ of
ranked pos subtract pre treatment HbA1c. Analysis used paired-t by column; and intra-assay used KruskaleWallis by raw.
Significant values in bold §P < 0.1; *P < 0.05; **P < 0.01.
Table 4
Period III convenient assignment HbA1c mmol/mol.
P1&CC AG&CC AG&P2 TA Respective mean
rank
KruskaleWallis c2
n ¼ 17 n ¼ 27 n ¼ 8 n ¼ 22
PreTx HbA1c 43.1 ± 11.0 40.3 ± 6.9 36.8 ± 2.3 41.2 ± 8.1 39, 39, 22, 40 5.02
PosTx HbA1c 46.1 ± 11.5 42.2 ± 8.2 39.1 ± 3.5 41.2 ± 7.8 46, 37, 26, 36 5.5
Diff. low-up 95% CI ¡3.2 to ¡0.5* ¡3.2 to ¡0.5* ¡4.9 to 0.3x 3.0 to 2.8 46, 35, 40, 33 4.4
AG ¼ Aloe gel; CC ¼ Cnidoscolous chayamansa infusion; TA ¼ concentrated 5:1 Aloe gel by total process; P ¼ placebo (1 and 2).
PreTx ¼ pretreatment; PosTx ¼ post treatment. Data: mean ± SD, and between groups mean rank.
Drop out: 4, 2, 2, 4 subjects, respectively; these counted as failure (HbA1c increase 5.47 mmol/mol). Paired t andWilcoxon test CI
were significant (bold); §P < 0.1; *P < 0.05; **P < 0.01. LCOF for missing, TA vs the rest, change A1c were:0.94 ± 6.0 vs 1.5 ± 4.6,
Diff. Low-Up 95% CI ¡0.03 to 5.1, t ¼ 2.0, P ¼ 0.053.
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neither reaching significance. Still, using LOCF for missing data, TA (n ¼ 22) vs the rest combined
(n ¼ 52) was better in achieving euglycemia: 0.94 ± 6.0 vs 1.6 ± 4.6 mmol/mol, F ¼ 0.7, t ¼ 2.0,
df ¼ 72, P ¼ 0.053 (95% CI  5.11 to 0.03.mmol/mol).
Table 5
hs-CRP (mg/dl) Mean ± SD by treatment for period I and II. In the lower part period III.
Period I and II AG&CC
n ¼ 46
P1&P2
n ¼ 49
KW
c2
AG&P2
n ¼ 46
P1&CC
n ¼ 46
KW
c2
TA
n ¼ 26
P3
n ¼ 25
KW
c2
PreTx 5.4 ± 4.1 5.3 ± 4.9 0.28 5.4 ± 4.5 5.5 ± 5.4 0.31 7.9 ± 6.6 6.2 ± 5.8 1.17
PostTx 6.2 ± 5.5 5.1 ± 4.1 0.38 5.4 ± 4.3 5.8 ± 5.6 0.01 5.2 ± 4.2 7.1 ± 5.5 1.23
Diff. low-up
95% CI
2.0 to 0.5 0.6 to 0.9 1.9 1.4 to 1.3 1.4 to 0.9 1.31 0.5 to 5.0* 3.3 to 1.5 9.38**
Period III AG&CC n ¼ 27 AG&P2, n ¼ 8 P1&CC, n ¼ 17 TA n ¼ 22 KW
c2
PreTx 4.5 ± 4.9 5.0 ± 2.8 5.7 ± 4.2 4.8 ± 4.3 3.0
PostTx 4.1 ± 4.0 4.8 ± 3.2 5.3 ± 4.0 3.6 ± 3.6 3.0
Diff. low-up
95% CI
1.2 to 1.9 2.2 to 2.6 0.8 to 1.7 0.2 to 2.0* 1.27
AG ¼ Aloe gel; CC¼ Cnidoscolous chayamansa infusion; TA ¼ concentrated 5:1 AG by total process; P ¼ placebo (1, 2 and 3);
PreTx ¼ pre-treatment level and PostTx ¼ post-treatment level. Period III had a single blinded convenient assignment. LOCF for
missing data. Data: median, sum of () and (þ) ranked treatment difference. Analysis: Paired t by column, and between groups
intra-assay KruskaleWallis. Significant values in bold §P < 0.1; *P < 0.05; **P < 0.01.
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hs-CRP changes are shown in Table 5. A data point to significant improvement was found only for TA
and were statistically divergent for its counterpart; replicating significant hs-CRP reduction in period
III. For AG&P2 there were no significant hs-CRP changes. For comparisonwith Zhang Yet al. [15], HbA1c
was transformed to average blood glucose values in mg/dl using the equation of Nathan et al. [16]. This
is described in Table 6, combining the three periods, along with hs-CRP, body weight, BMI, Tri-
glycerides, and HDL. Body weight and BMI improved only in the AG&CC and AG&P2 groups. All tri-
glyceride changes were insignificant, while HDL decreased significantly across all treatments. Mean
blood glucose was significantly reduced for TA and AG&P2. A one-tailed Dunnett's procedure shows
significantly better reduction for TA than AG&CC and P1&CC but no significant deviation from AG&P2.
These differences were (mean ± SE) 7.2 ± 3.2, P < 0.05*; 6.1 ± 3.2, P < 0.1x; 3.3 ± 3.4, P > 0.3,
respectively.Table 6
Concomitant changes by treatment in 3 periods pooled.
Treatment n hs-CRP mg/dl Bodyweight, kg BMI kg/m2 Triglycerides
mg/dl
HDL mg/dl BG mg/dl
P1&CC 63 PreTx 5.5 ± 5.0 82.1 ± 14.3 34.1 ± 5.3 113.3 ± 58.5 44.8 ± 8.0 131.4 ± 26.7
PosTx 5.6 ± 5.2 81.9 ± 14.4 34.0 ± 5.4 120.3 ± 65.7 42.5 ± 5.9 128.2 ± 24.5
Diff Low-up
95% CI
0.9 to 0.8 0.2 to 0.6 0.1 to 0.2 17.2 to 2.8 0.6 to 4.2* 1.5 to 8.0
AG&CC 73 PreTx 5.1 ± 4.4 79.1 ± 12.2 33.0 ± 4.3 126.2 ± 78.9 43.8 ± 7.2 128.8 ± 22.2
PosTx 5.4 ± 5.1 78.5 ± 12.3 32.8 ± 4.4 130.4 ± 102.6 41.6 ± 5.9 127.0 ± 21.3
Diff Low-up
95% CI
1.3 to 0.6 0.2 to 0.9** 0.1 to 0.4** 16.3 to 7.7 0.5 to 3.9* 1.8 to 5.9
AG&P2 54 PreTx 5.4 ± 4.3 80.7 ± 12.7 33.5 ± 5.2 112.7 ± 63.1 45.8 ± 9.8 129.3 ± 19.4
PosTx 5.4 ± 4.1 80.3 ± 12.9 33.4 ± 5.2 113.7 ± 59.1 43.4 ± 6.3 123.0 ± 18.5
Diff Low-up
95% CI
1.2 to 1.1 ¡0.05 to 0.8x ¡0.01 to 0.3x 8.5 to 6.4 0.1 to 4.6* 2.2 to 9.7**
TA 48 PreTx 6.5 ± 5.8 79.1 ± 16.0 32.6 ± 5.2 113.3 ± 61.8 44.4 ± 6.1 134.7 ± 38.2
PosTx 4.5 ± 3.9 79.5 ± 16.2 32.8 ± 5.4 115.2 ± 75.0 42.4 ± 6.0 125.4 ± 32.4
Diff Low-up
95% CI
0.7 to 3.3** 0.95 to 0.1 0.4 to 0.02 11.4 to 7.7 0.4 to 3.7* 3.8 to 14.7**
AG¼ Aloe gel; CC¼ Cnidoscolous chayamansa infusion; TA¼ concentrated 5:1 AG by total process; P¼ placebo (1, 2 and 3). LOCF
used for missing data. Paired t significant values in bold, §P < 0.1; *P < 0.05; **P < 0.01. One side Dunnett's TA best lowering vs
table order diff (difference) ± SE of hs-CRP 1.7± 0.8*, 2.1± 0.7**, 1.7± 0.8*; and BGmg/dl: 6.0± 3.3§, 7.3± 3.2*, 3.3 ± 3.4. About
BMI, TA was indifferent to P1&CC, but higher than AG&CC and AG&P2 diff (difference) ± SE: 0.25 ± 0.13, 0.43 ± 0.12*,
0.35 ± 0.13* k/m2. Lipids had insignificant differences.
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outs were counted as failures (R ¼ 0.829, adjusted r2 ¼ 0.67, F ¼ 63.3, P < 0.001). The stepwise selected
predictors were: constant, pre-treatment HbA1c level, post-treatment hs-CRP, SE (0 ¼ none, 1 ¼ any)
and aloe dose (0 ¼ none, 1 ¼ AG and 2 ¼ TA); beta coefficients (±SD) were 15.8 ± 2.2, 0.58 ± 0.05,
0.36 ± 0.12, 4.0 ± 1.4 and 2.0 ± 0.81, respectively; each P < 0.05. Non predictors were CC (0 ¼ none,
1 ¼ 200 or 400 ml of CC infusion), change of BMI kg/m2, triglycerides and HDL mg/dl. Using LCOF for
missing data, adjusted r2 ¼ 0.7, and the side effects stopped being a predictor variable.
4. Discussion
These three double-blind randomized 2-sequence, 2-periods, and 2-treatment crossover assays in
women with EMS show a clinical and statistically significant reduction of hyperglycemia and hs-CRP
levels with TA (the concentrated 5:1 aloe gel) in each of two treatment periods and it sustained
euglycemia in Period III. The tendency for improvement with AG&P2 faded in period II. Doubling the
dose generated a bad taste and mild stomach pain and caused patients to drop out; however, 57%
managed to tolerate it and using LOCF for drop outs, a small but significant hyperglycemia reduction
was seen (P < 0.05). On the other hand, most subjects with CC treatments felt an increase in wellbeing
and their energy level without significant HbA1c changes (P > 0.1). This significantly worsened in
period III (P < 0.05). It seems that CC counteracts the AG hypoglycemic effect and the intolerance
observed in AG without CC. In spite of the fact that AG&CC was the most tolerated treatment (highest
rank of sensed wellbeing and energy levels), it failed to reduce hyperglycemia. Indeed, LOCF for
dropouts, AG&CC (n¼ 73) was statistically worse than placebo (P1&P2, n¼ 49), mean rank 67.0 vs 53.3,
respectively, KeW c2 ¼ 4.4, df1, P < 0.05.
The HbA1c change was influenced by the prescribed 1500 calorie diet, participant eagerness for
herbal remedies, pretreatment extent of hyperglycemic level and treatment effect. The observed
change in trend suggests that the first two predominate with CC and placebo treatments, while the last
two predominate with TA and AG&P2. Regarding the dose, a comparison of both significant im-
provements, in period I, TA vs AG&P2 were similar; corresponding to a mean blood glucose change
18.7 ± 25.1 vs 8.6 ± 16.5 mg/dl respectively, t ¼ 1.5, df ¼ 35, P > 0.15; but two gelatins/day were not
tolerable because of bad taste and mild stomach pain for AG and did produce a greater reduction in
glucose levels for TA. Thus, the greatest reduction in glycemia and the best tolerance was with the
30 mL dose of TA.
Our aloe findings are in agreement with the report by Yongchaiyudha et al. [17] reducing fasting
hyperglycemia in new cases of diabetes mellitus. Choudhary et al. [18] also reported a reduction of
hyperglycemia and hyperlipidemia after 3 months of intake of aloe gel powder plus diet in male pa-
tients with newly diagnosed non-insulin dependent diabetes. Also, Choi et al. [19] reported a lowering
of body weight, insulineresistance, and almost hypoglycemic effects with 600 mg/day of aloeQDM-
complex for 8 weeks in obese prediabetic patients. Similar to them, AG&P2 in this study, with shorter
treatment periods, showed a reduction of BMI and hyperglycemia, while TA exhibited hs-CRP lowering
and twice the improvement of hyperglycemia than AG with an insignificant change in BMI. This agrees
with the mechanism proposed by Yagi et al. [20] who reported an anti-hyperglycemic effect after 12
weeks of treatment with aloe, possibly by activation of the immune system. Also, a glycoprotein from
aloe (verectin) with anti-oxidative, anti-thromboxane A2 synthase inhibition, and cyclooxigenase-2
inhibiting activities was isolated. In 2008, Hamman [5] described the anti-inflammatory and immu-
nomodulatory effects of acetylated mannan (acemanan). The chromatography of TA used in this study,
indicates that it contains 8.77% acemannan, and almost 34% of molecular species (where “verectin”, a
glycoprotein of 14 kDa, could be found). Adipocyte cytokine insulin resistance has been linked to hs-
CRP pro-inflammatory levels [21,22]. Other Authors [23,24] link impaired insulin sensitivity with
oxidative stress, thus a new approach could be medical food. Aloe polysaccharides have shown po-
tential to modulate the oxidative-immflamatory cascade in diabetes [25].
This study favors TA, and to a less extent, AG as anti-hyperglycemic agents. This could strengthen
the meta-analysis by Zhang et al. [15] although insignificant changes of the lipid profile are probably
due to insufficient treatment duration. In fact, the HDL decline across treatments is probably related to
the 1500-calorie diet plan prescribed to all than to CC or aloe.
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effect of gelatin, and 2) in the case of aloe through the intact polysaccharides (mannan) reaching the
colon and acting as prebiotics, promoting healthier bacterial flora and ease in bowel movements as has
been suggested by Gullon et al. [25] and Suez et al. [26].
This study did not show a reduction of hyperglycemia, lipids or hs-CRP by the gelatins containing an
infusion of microwave dehydrated CC leaves (200 or 400 ml), contrary to the observations of Kuti and
Torres in an animal model [8]. However, our subjects reporting increased alertness, vivid dreams, and
sleep disturbances (both categorized as insomnia in Table 1) that suggest brain stimulating compounds
with 200 and 400 ml of the CC infusion; thus it may be unwise to increase the dose. Kuti and Torres
provided fresh leaves ad libitum [8]. Loarca-Pi~na et al. [27] reported a hypoglycemic effect in diabetic
rats with intra-gastric 70 mg/kg of methanolic CC extract. Also, Ramos-Gomez et al. [28] with a 2% w/v
aqueous extract of CC in diabetic rats reported a reduction of hyperglycemia and lipid levels but the
extract caused microalbuminuria after long-term intake. The CC infusionwith microwaved dehydrated
leaves had a color and taste like an infusionwith naturally dehydrated CC leaves (the way most people
use it), both hide similarly in gelatin; but the microwave damaging CC anti-diabetic effect cannot be
disproven.
Some of the limitations of the study were 1) the short treatment period, which did not allow a
desirable demonstration of obesity and dyslipidemia reduction; also 3 months are needed to observe a
full hemoglobin exchange, since the A1c fraction is otherwise irreversible; 2) all participants were
sedentarywith no physical activity and no attemptwasmade to change this; 3) a calorie restriction diet
was prescribed for all with this being pivotal to managemetabolic syndrome; to not prescribe it would
be unethical, and 4) a longer wash-out period is needed. One week was not enough to return to basal
levels. Nonetheless, our findings encourage continuing aloe studies and discarding microwave dehy-
dration of CC leaves.
Keeping in mind the above mention limitations, the results can be safely applicable to other obese
subjects with EMS. Here, only women were enrolled but Choudhary et al. [18]. studied only men
successfully. Longer observations are needed to reveal a sustained effect in reducing levels of hyper-
glycemia and hs-CRP.
5. Conclusions
Data propose that 30 ml of TA has an anti-hyperglycemic and CRP reduction effect and is well
tolerated as functional food. AG had a less significant anti-hyperglycemic effect but did not diverge
from the rest, due to a large dropout rate. The gelatins with microwave dehydrated leaves for CC
infusion tended to be worse than placebo for reducing hyperglycemia. Thus, TA concentrated AG could
help decrease glucose intolerance by lowering CRP, and warrants in-depth studies to determine if this
functional food can keep HbA1c normal to prevent progression to diabetes and to clarify aloe mech-
anisms in reducing hyperglycemia.
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